Physician profile
Brian Steven Thamel
NPI 1508927054
$4,038.59
in general payments reported to CMS, 2019-2025
18 companies · $588 in 2025
The $588 reported for 2025 was more than what 87% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $211 · 2021: $494 · 2022: $662 · 2023: $644 · 2024: $727 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $975.68 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $565.85 | 2022-2025 | Total30, Precision7, Precision 7 |
| Optovue, INC. | $341.32 | 2019-2020 | |
| Oyster Point Pharma, INC. | $314.64 | 2022-2023 | Tyrvaya |
| Rxsight INC | $270.76 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $211.73 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $184.23 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $182.80 | 2019-2021 | |
| Abbvie INC. | $160.86 | 2022-2024 | Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $150.71 | 2023-2025 | Cequa |
| Carl Zeiss Meditec USA, INC. | $127.61 | 2021 | |
| Lkc Technologies, INC. | $124.69 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $121.85 | 2025 | Xdemvy |
| Maculogix, INC. | $96.27 | 2019-2020 | |
| Sight Sciences, INC. | $89.98 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $56.02 | 2021-2022 | |
| Optos, INC. | $40.34 | 2022 | |
| Lombart Brothers, INC. | $23.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Thamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.